Biotech · Private company · Burlington, MA, US

scPharmaceuticals Inc.

SEC CIK 0001604950

Track this companyFree. Adds scPharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials60 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline6

Furoscix InfusorPhase 3 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
Furosemide Injection, USPPhase 3 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
Fursemide Injection Solution for subcutaneous administration (80 mg)Phase 3 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
Furosemide 80 mg (8 mg/mL)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Furosemide USPPhase 1 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
SCP-111Phase 1 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy VolunteersPHASE1 · COMPLETED · started Apr 19, 2024ClinicalTrials.gov NCT06167707 · fetched Nov 12, 2026
Furoscix in Heart Failure Patients With Diuretic ResistancePHASE2 · COMPLETED · started Jun 2, 2023ClinicalTrials.gov NCT05528588 · fetched Nov 12, 2026
Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot StudyPHASE2 · COMPLETED · started May 3, 2021ClinicalTrials.gov NCT04593823 · fetched Nov 12, 2026
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart FailurePHASE3 · COMPLETED · started Nov 12, 2020ClinicalTrials.gov NCT03458325 · fetched Nov 12, 2026
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin TolerabilityPHASE1 · COMPLETED · started Dec 2, 2019ClinicalTrials.gov NCT04161482 · fetched Nov 12, 2026
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart FailurePHASE2_PHASE3 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02329834 · fetched Nov 12, 2026